Trial Profile

A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-finding Study to Evaluate the Efficacy and Safety of IMU-838 for Induction and Maintenance Therapy in Moderate-to-severe Ulcerative Colitis

Status: Discontinued

Phase of Trial: Phase II

Latest Information Update: 30 Aug 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

30 Aug 2024 This trial has been completed in Portugal (Global end date: 16 Nov 2022).
17 Oct 2023 Results of Efficacy and Safety of Vidofludimus Calcium (Imu-838) in Patients with Moderately to Severely Active Ulcerative Colitis , presented at the 31st United European Gastroenterology Week
16 Oct 2023 According to an Immunic media release, the company announced the presentation of data from this study in an oral prresentation at the United European Gastroenterology Week (UEGW) 2023, taking place October 14-17 in Copenhagen.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com